Compare LEG & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | TRVI |
|---|---|---|
| Founded | 1883 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2018 | 2019 |
| Metric | LEG | TRVI |
|---|---|---|
| Price | $10.20 | $10.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $10.50 | ★ $20.38 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 145.31 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $5,203,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.85 | N/A |
| P/E Ratio | $6.04 | ★ N/A |
| Revenue Growth | ★ 1.37 | N/A |
| 52 Week Low | $6.48 | $4.85 |
| 52 Week High | $13.00 | $14.39 |
| Indicator | LEG | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 42.93 |
| Support Level | $8.59 | $10.04 |
| Resistance Level | $10.66 | $11.78 |
| Average True Range (ATR) | 0.32 | 0.73 |
| MACD | -0.13 | -0.11 |
| Stochastic Oscillator | 4.09 | 3.83 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.